207 results
10-K
2016 FY
EX-10.16
ADAP
Adaptimmune Therapeutics Plc
13 Mar 17
Annual report
12:00am
similar proceedings with respect to that Patent;
Prosecuting Party
means the Party responsible for Prosecution under Clauses 12.2 and 12.3 … JPT. The JPT for each Selected Target and corresponding Co-Development Plan shall be responsible for governing the day to day performance
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells … ). Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.
Under the terms of the agreement, Adaptimmune
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
, the defense of oppositions and other similar proceedings with respect to that Patent;
Prosecuting Party
means the Party responsible for Prosecution under … . The sub-contracting Party will remain fully responsible (at its cost) for all acts or omissions of any sub-contractor it appoints (including any
DRS
EX-10.2
1fnoe37yd1t nt2
5 Feb 15
Draft registration statement
12:00am
UPLOAD
qb2y4pjx c64o01410
6 Apr 23
Letter from SEC
12:00am
UPLOAD
wlwt03h0 j95v
6 Sep 19
Letter from SEC
12:00am
20-F
EX-4.14
mmeehl4xh a9
13 Oct 15
Annual report (foreign)
12:00am
8-K
EX-99.1
ghodo4au
24 Jul 18
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
7:36am
20-F
EX-4.13
dd5rnstxs pmkr
13 Oct 15
Annual report (foreign)
12:00am